Targeting ER-Golgi Homeostasis in an Advantageous Therapeutic Strategy in Lung Cancer

Clinical trial NCT01270399 · UNKNOWN

Trial details

NCT number: NCT01270399
Sponsor: Meir Medical Center
Status: UNKNOWN
Study type: OBSERVATIONAL

The Combined Effect of Hsp90 Inhibitor and HDAC/Proteasome Inhibitors on Lung Cancer Cell Fate and ER-Golgi Homeostasis Will be Examined.

Start date: 2011-01-01
Primary completion: 2013-01-01
Enrollment: 20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.